0
Please log in or register to do it.

Samsung Bioepis headquarters building

Samsung Bioepis headquarters building

(Seoul = Larose.VIP) Reporter Cho Hyun-young = Samsung Bioepis’ biosimilar (biopharmaceutical generic drug) products achieved record-high sales in overseas markets last year.

According to the company’s overseas partners, American pharmaceutical companies Biogen and Organon, on the 18th, Samsung Bioepis’ six biosimilars generated sales of $1.363 billion (approximately KRW 1.8 trillion) overseas, including in the U.S. and Europe. recorded.

This is an 11% increase compared to 2022 sales of $1.2321 billion (approximately 1.6 trillion won). Product sales through Biogen were $770 million, a 3% increase from the year before last, and product sales through Organon were $593 million, a 23% increase over the same period.

The products sold overseas by Samsung Bioepis include biosimilars of autoimmune disease treatments Enbrel, Humira, and Remicade, biosimilars of the anticancer drugs Herceptin and Avastin, and biosimilars of ophthalmic disease treatment Lucentis.

Biogen sells three types of autoimmune disease treatments in Europe and one type of eye disease treatment in the United States, and Organon sells three types of autoimmune disease treatments in the U.S., Australia, and Canada and two types of anticancer drugs in the U.S. and Europe.

Samsung Bioepis receives a certain percentage of product sales as profit according to the partnership agreement with the two companies. Due to this influence, Samsung Bioepis recorded its highest ever performance of 1.0203 trillion won in annual sales and 205.4 billion won in operating profit last year.

Excluding diagnostic kit companies, there are about nine pharmaceutical and bio companies in Korea that have achieved annual sales of KRW 1 trillion, and Samsung Bioepis was added to the list in an unusually fast 12 years since its founding.

Samsung Bioepis expected the growth of ‘Hadrima’, a biosimilar to the autoimmune disease treatment Humira, this year.

As of December last year, Hadrima achieved the No. 1 market share in the U.S. Humira biosimilar market. Samsung Bioepis has applied for interchangeability approval for Hadrima to allow U.S. pharmacies to prescribe Humira as an alternative without doctor intervention. According to Organon, approval is expected within the next four months.

Samsung Bioepis said, “As product sales in overseas markets continue to grow, we expect Samsung Bioepis’ sales to increase this year.”

Overseas sales of Samsung Bioepis biosimilar products grew from $1.125.7 billion in 2020 to $1.255.1 billion in 2021. In 2022, sales slightly decreased to $1.2321 billion, but recovered in 2023 and recorded the highest sales.

hyun0@yna.co.kr

Report to KakaoTalk okjebo 2024/02/18 07:00 Sent

Concerned views on the K-pop market in the new year... Album sales decline amid ‘Corporate Variables’
85% of wild animals distributed are blind spots in management… “Regulate by creating a white list”

Reactions

0
0
0
0
0
0
Already reacted for this post.

Reactions

Your email address will not be published. Required fields are marked *